Occlusion of the left atrial appendage provides protection against thromboembolic stroke in patients with nonvalvular atrial fibrillation.
PCSK9 inhibitors may offer hope to patients with familial hypercholesterolemia who cannot tolerate or achieve goal LDL-C levels with statins.
Choosing the right anticoagulant agent can be a challenge for many reasons, including cost, familiarity, drug interactions, and reversibility.
Risk and prevalence of stroke in patients with undiagnosed asymptomatic atrial fibrillation remains problematic for patients and clinicians.
The American Association of Clinical Endocrinologists site lack of evidence of cardiovascular disease risk in testosterone therapy use.
Guidelines for hypertension management during acute stroke are based on clinician experience.